An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Singapore has updated the official information for Wegovy to include data from studies using a higher dose of semaglutide that showed people lost as much as 25% of their body weight. In plain terms, the government-health authority in Singapore has allowed the drug’s label — the factsheet that comes with a medicine — to mention results from research where a stronger dose produced bigger weight loss than the dose commonly used now. Semaglutide is the active ingredient in medications like Ozempic and Wegovy. It’s a synthetic version of a natural chemical your gut makes after you eat. That chemical talks to the brain to reduce appetite and slow how fast the stomach empties. In other words, people feel less hungry and fuller for longer. Semaglutide works by switching on a specific “receptor” in the body (a kind of molecular lock), and the drug acts like a key to turn that lock more strongly or more often. The announcement refers to study data at a higher dose showing up to 25% weight loss. The snippet doesn’t spell out the study size, how long it ran, or whether the work was done in people or animals, so we can’t assume details that weren’t provided. Historically, semaglutide trials in humans have produced significant weight loss when given over many months, and higher doses tend to give bigger effects, but the precise numbers, participant characteristics, and side-effect rates for this specific higher-dose research aren’t included in the short news line you shared. Why this matters is straightforward: if higher doses reliably produce greater weight loss with an acceptable safety profile, that could change treatment choices for people with obesity or related conditions. Doctors and patients might consider different dosing strategies, and regulators or insurers could re-evaluate approvals and coverage. For people struggling to lose weight, better options may become available; for clinicians, it’s more information to weigh when recommending therapies. There are important caveats. Higher doses can bring stronger or more frequent side effects, such as nausea, vomiting, diarrhea, or more serious risks that need careful monitoring. The snippet doesn’t say regulatory agencies outside Singapore have made the same label change, nor does it confirm long-term safety. Also, who should or shouldn’t take stronger doses depends on individual health, other medicines being taken, and medical history. Always consult a doctor rather than assuming a higher dose is right for you. Bottom line: Singapore’s label change means there’s new, higher-dose semaglutide data showing up to 25% weight loss, but the brief announcement leaves out key study details and safety context, so this is promising news that still needs careful, individualized medical judgment.
Source: BioPharma APAC